公开(公告)号：US11441164B2

公开(公告)日：2022-09-13

申请号：US17099539

申请日：2020-11-16

申请人： CB Therapeutics, INC.

发明人： Jacob Michael Vogan ,  Laura Flatauer Peiffer ,  James Lee Wade ,  Tyrone Jacob Yacoub ,  Kirsten Tang ,  Rachel Nadine Burnett

IPC分类号： C12P17/10 ,  C12N9/88 ,  C12N9/02 ,  C12N9/12 ,  C12N9/10 ,  C12N1/20 ,  C12N15/00 ,  C12N1/16 ,  C12N15/81

摘要： The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.

公开(公告)号：US20230242919A1

公开(公告)日：2023-08-03

申请号：US18000931

申请日：2021-06-04

申请人： CB Therapeutics, Inc.

发明人： Laura Flatauer Peiffer ,  Jacob Michael Vogan ,  James Lee Wade ,  Tyrone Jacob Yacoub ,  Kirsten Tang ,  Rachel Nadine Burnett

IPC分类号： C12N15/52 ,  C12N15/81 ,  C12N15/82

CPC分类号： C12N15/52 ,  C12N15/815 ,  C12N15/8254 ,  C12Y201/01049 ,  C12Y207/04003 ,  C12Y401/01028

摘要： Provided are non-naturally occurring nucleic acids comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism. Also provided are a recombinant microorganisms expressing the enzyme or regulatory protein. Methods of expressing the enzyme or regulatory protein are additionally provided.

公开(公告)号：US20220389467A1

公开(公告)日：2022-12-08

申请号：US17878858

申请日：2022-08-01

申请人： CB Therapeutics, INC.

发明人： Jacob Michael Vogan ,  Laura Flatauer Peiffer ,  James Lee Wade ,  Tyrone Jacob Yacoub ,  Kirsten Tang ,  Rachel Nadine Burnett

IPC分类号： C12P17/10 ,  C12N1/16 ,  C12N15/81 ,  C12N9/10 ,  C12N9/88 ,  C12N9/12 ,  C12N9/02

摘要： The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.

公开(公告)号：US20210147888A1

公开(公告)日：2021-05-20

申请号：US17099539

申请日：2020-11-16

申请人： CB Therapeutics, INC.

发明人： Jacob Michael Vogan ,  Laura Flatauer Peiffer ,  James Lee Wade ,  Tyrone Jacob Yacoub ,  Kirsten Tang ,  Rachel Nadine Burnett

IPC分类号： C12P17/10 ,  C12N1/16 ,  C12N9/10 ,  C12N15/81

摘要： The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.